Stockscreener 앱 받기
5.91
0.84%
-0.05
시간 외 거래:
5.91
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Advanced analytics toolkit walkthrough for Candel Therapeutics Inc.Weekly Profit Analysis & Real-Time Chart Pattern Alerts - Newser
Live market analysis of Candel Therapeutics Inc.July 2025 Big Picture & Smart Swing Trading Alerts - Newser
Is a relief rally coming for Candel Therapeutics Inc. holders2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
Heatmap analysis for Candel Therapeutics Inc. and competitorsIndex Update & Accurate Entry/Exit Alerts - Newser
Published on: 2025-08-27 01:40:12 - Newser
What’s the recovery path for long term holders of Candel Therapeutics Inc.2025 Market Outlook & Daily Stock Trend Watchlist - Newser
Sector ETF performance correlation with Candel Therapeutics Inc.July 2025 News Drivers & Safe Swing Trade Setup Alerts - Newser
Sector ETF performance correlation with Candel Therapeutics IncGlobal Markets & Risk Managed Investment Signals - Newser
Real time pattern detection on Candel Therapeutics Inc. stock2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Is Candel Therapeutics Inc. stock entering bullish territoryGold Moves & Free AI Powered Buy and Sell Recommendations - Newser
Applying Wyckoff theory to Candel Therapeutics Inc. stockWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Using Bollinger Bands to evaluate Candel Therapeutics Inc.Weekly Investment Report & Fast Momentum Entry Tips - Newser
Is Candel Therapeutics Inc. benefiting from interest rate changes2025 Technical Patterns & Daily Volume Surge Trade Alerts - theviewers.co.kr
What to expect from Candel Therapeutics Inc. in the next 30 daysCPI Data & AI Based Buy/Sell Signal Reports - Newser
Candel Therapeutics' Lease Extension: A Strategic Anchor for R&D and Investor Confidence in a Volatile Biotech Landscape - AInvest
Candel Therapeutics extends lease term to Aug 31, 2029 - MarketScreener
Candel Therapeutics Extends Lease Agreement in Needham - TipRanks
Chartists See Breakout Potential in Candel Therapeutics Inc.2025 Support & Resistance & Growth Oriented Trade Recommendations - beatles.ru
Candel Therapeutics Insider Ups Holding By 22% During Year - simplywall.st
Automated trading signals detected on Candel Therapeutics Inc.Market Activity Report & Daily Profit Maximizing Trade Tips - Newser
Candel Therapeutics shares rise 3.42% after-hours following FDA's rejection of PTC Therapeutics' drug. - AInvest
Candel Therapeutics Advances with Promising Cancer Therapies - TipRanks
Bullish Candlestick Pattern Forms in Candel Therapeutics Inc.Price Action & AI Driven Price Predictions - classian.co.kr
Candel Therapeutics Posts Q2 2025 Loss, But History Suggests Strong Post-Earnings Recovery Potential - AInvest
How institutional ownership impacts Candel Therapeutics Inc. stockJuly 2025 Market Mood & AI Forecasted Entry/Exit Points - Newser
Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment - MSN
Candel Therapeutics Posts Loss in Q2 2025; Surprising Market Resilience Sparks Investor Interest - AInvest
Does Candel Therapeutics Inc. show high probability of rebound2025 Winners & Losers & AI Driven Stock Reports - Newser
Candel Therapeutics secures RMAT for prostate cancer – ICYMI - Proactive financial news
Candel Therapeutics reports Q2 EPS (9c) vs. (74c) last year - MSN
Candel Therapeutics Inc. Matches Institutional Buying Filter2025 Market Outlook & Long-Term Investment Growth Plans - newsyoung.net
Candel Therapeutics: Promising Pipeline Developments and Strategic Advancements Support Buy Rating - TipRanks
Candel eyes 2026 U.S. filing for CAN-2409 after Phase 3 success and FDA RMAT status - Proactive financial news
Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential - TipRanks
Candel Therapeutics shares fall 5.16% intraday despite positive clinical trial results and regulatory designations. - AInvest
Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Small cap wrap: Lancaster Resources, Candel Therapeutics, atai Life Sciences, Charbone Hydrogen... - Proactive financial news
Candel Therapeutics sees cash runway into 1Q27 - TipRanks
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Candel Therapeutics Advances Prostate Cancer Therapy Filing After Successful Trial - AInvest
Candel Therapeutics advances toward prostate cancer therapy filing after trial success - Proactive financial news
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
Candel's Prostate Cancer Treatment Secures FDA Fast Track After Breakthrough Trial Results - Stock Titan
Can Candel Therapeutics Inc. be recession proofJuly 2025 Sentiment & Low Drawdown Investment Strategies - classian.co.kr
Can Candel Therapeutics Inc. grow without dilutionWeekly Gains Report & Long Hold Capital Preservation Plans - newsyoung.net
Candel Therapeutics Inc. Stages Intraday Comeback — Trend ChangeReal Trader Watchlist of Hot Stocks Released - beatles.ru
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Candel Therapeutics Institutional Ownership Soars to 44%: Implications for Stock Price Sensitivity - AInvest
Candel Therapeutics shares fall 2.76% intraday after announcing clinical trial initiation for tecarfarin in dialysis patients. - AInvest
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
0.98%
8.06%
자본화:
|
볼륨(24시간):